Last reviewed · How we verify
TPC combined with Tislelizumab
TPC combined with Tislelizumab is a Chemotherapy + PD-1 inhibitor combination Small molecule drug developed by XIANG YANQUN. It is currently in Phase 3 development for Advanced or metastatic solid tumors (specific indication under investigation in Phase 3).
TPC combined with Tislelizumab uses chemotherapy to damage cancer cells while Tislelizumab blocks PD-1 to enhance immune recognition and attack of tumors.
TPC combined with Tislelizumab uses chemotherapy to damage cancer cells while Tislelizumab blocks PD-1 to enhance immune recognition and attack of tumors. Used for Advanced or metastatic solid tumors (specific indication under investigation in Phase 3).
At a glance
| Generic name | TPC combined with Tislelizumab |
|---|---|
| Sponsor | XIANG YANQUN |
| Drug class | Chemotherapy + PD-1 inhibitor combination |
| Target | PD-1 (Tislelizumab component); TPC targets DNA/cell cycle |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TPC (a chemotherapy regimen) provides direct cytotoxic effects against cancer cells. Tislelizumab is a humanized PD-1 inhibitor that blocks the programmed death-1 checkpoint, preventing tumor cells from suppressing T-cell immunity. The combination leverages chemotherapy's direct cell-killing activity with immunotherapy's ability to reinvigorate anti-tumor immune responses.
Approved indications
- Advanced or metastatic solid tumors (specific indication under investigation in Phase 3)
Common side effects
- Fatigue
- Nausea/vomiting
- Myelosuppression
- Immune-related adverse events (irAEs)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TPC combined with Tislelizumab CI brief — competitive landscape report
- TPC combined with Tislelizumab updates RSS · CI watch RSS
- XIANG YANQUN portfolio CI
Frequently asked questions about TPC combined with Tislelizumab
What is TPC combined with Tislelizumab?
How does TPC combined with Tislelizumab work?
What is TPC combined with Tislelizumab used for?
Who makes TPC combined with Tislelizumab?
What drug class is TPC combined with Tislelizumab in?
What development phase is TPC combined with Tislelizumab in?
What are the side effects of TPC combined with Tislelizumab?
What does TPC combined with Tislelizumab target?
Related
- Drug class: All Chemotherapy + PD-1 inhibitor combination drugs
- Target: All drugs targeting PD-1 (Tislelizumab component); TPC targets DNA/cell cycle
- Manufacturer: XIANG YANQUN — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic solid tumors (specific indication under investigation in Phase 3)
- Compare: TPC combined with Tislelizumab vs similar drugs
- Pricing: TPC combined with Tislelizumab cost, discount & access